Abstract
Background
Patients with asthma who have persistent symptoms despite treatment with inhaled steroids and long-acting beta agonists are considered to have severe asthma. Omalizumab is a monoclonal antibody directed against IgE, which is used as an add-on treatment for patients who have severe persistent allergic asthma.
Aims
The aim of this study was to assess the clinical benefit and healthcare utilisation of patients who responded to omalizumab therapy and to establish an overall cost implication.
Methods
This was an observational retrospective cohort study designed to investigate the effect of omalizumab on exacerbations of asthma before and after 6 months of treatment in Irish patients.
Results
Centres who had treated patients with severe allergic asthma for the 6 months prior and post omalizumab treatment were audited with a standardised assessment tool. Sixty-three (32 male) patients were studied. In the 6 months prior to omalizumab 41 of 63 (66%) had been hospitalised, and this fell to 15 of 63 (24%), p < 0.0001 in the 6 months after treatment was started. Hospital admissions reduced from 2.4 ± 0.41 to 0.8 ± 0.37 and the mean number of bed days occupied was reduced from 16.6 ± 2.94 to 5.3 ± 2.57 days, p < 0.001. The number of oral corticosteroid doses used fell from 3.1 ± 0.27 to 1.2 ± 0.17, p < 0.001. The overall cost saving per omalizumab responder patients for 6 months was €834.
Conclusions
Six months therapy with omalizumab reduced the number of bed days, the number of hospitalisations and the use of oral corticosteroids compared to the 6 months prior to commencement. Despite the cost of the additional therapy there were overall savings in health costs.
Similar content being viewed by others
References
Heaney LG, Brightling CE, Menzies-Gow A et al (2010) Refractory asthma in the UK: cross-sectional findings from a UK multicentre registry. Thorax 65(9):787–794
Moore WC, Bleecker ER, Curran-Everett D et al (2007) Characterization of the severe asthma phenotype by the National Heart, Lung, and Blood Institute’s Severe Asthma Research Program. J Allergy Clin Immunol 119(2):405–413
Lloyd A, Price D, Brown R (2007) The impact of asthma exacerbations on health-related quality of life in moderate to severe asthma patients in the UK. Prim Care Respir J 16(1):22–27
Rodrigo GJ, Neffen H, Castro-Rodriguez JA (2011) Efficacy and safety of subcutaneous omalizumab vs placebo as add-on therapy to corticosteroids for children and adults with asthma: a systematic review. Chest 139(1):28–35
Firszt R, Kraft M (2010) Pharmacotherapy of severe asthma. Curr Opin Pharmacol 10(3):266–271
Brusselle G, Michils A, Louis R et al (2009) “Real-life” effectiveness of omalizumab in patients with severe persistent allergic asthma: The PERSIST study. Respir Med 103(11):1633–1642
Busse W, Corren J, Lanier BQ, McAlary M et al (2001) Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 108(2):184–190
Holgate S, Smith N, Massanari M (2009) Effects of omalizumab on markers of inflammation in patients with allergic asthma. Allergy 64(12):1728–1736
Molimard M, de Blay F, Didier A, Le Gros V (2008) Effectiveness of omalizumab (Xolair) in the first patients treated in real-life practice in France. Respir Med 102(1):71–76
Pinto JM, Mehta N, DiTineo M et al (2010) A randomized, double-blind, placebo-controlled trial of anti-IgE for chronic rhinosinusitis. Rhinology 48(3):318–324
Plewako H, Arvidsson M, Petruson K et al (2002) The effect of omalizumab on nasal allergic inflammation. J Allergy Clin Immunol 110(1):68–71
Royce SG, Tang ML (2009) The effects of current therapies on airway remodeling in asthma and new possibilities for treatment and prevention. Curr Mol Pharmacol 2:169–181
Schleich F, Manise M, Louis R (2009) Omralizumab (Xolair) in severe persistent allergic asthma. Rev Med Liege 64(5-6):313–317
Djukanovic R, Wilson SJ, Kraft M et al (2004) Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma. Am J Respir Crit Care Med 170(6):583–593
Fahy JV, Fleming HE, Wong HH et al (1997) The effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjects. Am J Respir Crit Care Med 155(6):1828–1834
Bradding P, Green RH (2010) Subclinical phenotypes of asthma. Curr Opin Allergy Clin Immunol 10(1):54–59
van den Berge M, Pauw RG, de Monchy JG et al (2011) Beneficial effects of treatment with anti-IgE antibodies (Omalizumab) in a patient with severe asthma and negative skin-prick test results. Chest 139(1):190–193
Acknowledgments
A non-promotional grant was provided by Novartis Pharmaceuticals for funding for the independent monitoring company Quintiles to perform the data acquisition on behalf of the authors. The authors also acknowledge the support of Helen Finnerty, Quintiles, O’Callaghan J., Nulty F., Connelly L., Hallahan P., O’Driscoll M F., Joyce R., Frawley T., Ruairi Herraghty, Gilles Ducorroy and Sandra Quinn of Novartis Pharmaceuticals for assistance in the study and to Professor Tom Pearce Midwestern Regional Hospital.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Costello, R.W., Long, D.A., Gaine, S. et al. Therapy with omalizumab for patients with severe allergic asthma improves asthma control and reduces overall healthcare costs. Ir J Med Sci 180, 637–641 (2011). https://doi.org/10.1007/s11845-011-0716-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11845-011-0716-2